diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index f0d0b2fdc..18234a658 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -115,21 +115,15 @@ International generic competition beginning January 2026 (Canada patent expiry, ### Additional Evidence (challenge) -*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy. ### Additional Evidence (challenge) -*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* -Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself. - - -### Additional Evidence (challenge) -*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* - -India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033. +If GLP-1 + exercise combination creates durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone) that persists after discontinuation, the chronic use economic model may be unnecessarily pessimistic. Value could accrue from shorter medication courses paired with intensive behavioral support, reducing long-term pharmaceutical spend while maintaining clinical benefits. --- diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 596ebca7e..19fe52b72 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -97,7 +97,7 @@ GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacol ### Additional Evidence (extend) -*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration. @@ -105,7 +105,7 @@ Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than pla ### Additional Evidence (extend) *Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* -Aon data shows benefits scale dramatically with adherence: for diabetes patients, medical cost growth is 6 percentage points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months overall, but 7 points lower with consistent use. Adherent users (80%+) show 47% fewer MACE hospitalizations for women and 26% for men. This confirms that adherence is the binding variable—the 80%+ adherent cohort shows the strongest effects across all outcomes, making low persistence rates even more economically damaging. +Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise (3.5 kg regain) maintains 60% more weight loss. This suggests the adherence paradox may be misframed—the economic value may not require chronic medication use if behavioral interventions create durable change that outlasts pharmacotherapy. --- diff --git a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index b0e625d2b..d068c7334 100644 --- a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -18,6 +18,10 @@ processed_by: vida processed_date: 2026-03-19 enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -102,3 +106,12 @@ EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison - At week 52 all intervention groups regained weight after stopping; by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg - Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) - ADA notes new therapies claiming 'enhanced quality of weight loss by improving muscle preservation' but no FDA-approved compounds with proven muscle preservation yet + + +## Key Facts +- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass +- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced +- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of interventions +- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy' +- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary, not FDA-approved) +- Weight regain by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg